Abstract
Background: Diabetes mellitus is a metabolic disease characterized by hyperglycemia due to impaired insulin secretion, often accompanied by hypercholesterolemia. Metformin is a first-line antihyperglycemic drug that is often combined with other antihyperglycemic drugs. Purple sweet potato leaves have been widely studied to reduce glucose and cholesterol levels. Methods: This study was an experimental study using rats induced with a high-fat diet and streptozotocin, which were divided into 8 treatment groups, namely groups given CMC Na 0.5%, Metformin 45 mg/kg BW, Purple Sweet Potato Leaf Extract (SPLE) 200 mg/kg BW, SPLE 400 mg/kg BW, SPLE 800 mg/kg BW, SPLE 200 mg/kg BW with metformin 45 mg/kg BW, SPLE 400 mg/kg BW with metformin 45 mg/kg BW, and SPLE 800 mg/kg BW with metformin 45 mg/kg BW. Results: After treatment for 28 days with SPLE doses of 200 mg, 400 mg, and 800 mg/kg BW, both single doses and combinations with metformin showed a decrease in fasting blood glucose levels and total cholesterol, which were statistically significantly different (p<0.05) between treatment groups using the one-way ANOVA. The combination of SPLE 800 mg/kg BW with metformin normalized blood glucose levels of 93.50±4.93 mg/dl. Conclusion: The combination of purple sweet potato leaf extract with metformin is more effective in reducing blood glucose and total cholesterol levels compared to the single administration of metformin and SPLE.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
More From: International Journal of Basic & Clinical Pharmacology
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.